Diese Präsentation wurde erfolgreich gemeldet.
Wir verwenden Ihre LinkedIn Profilangaben und Informationen zu Ihren Aktivitäten, um Anzeigen zu personalisieren und Ihnen relevantere Inhalte anzuzeigen. Sie können Ihre Anzeigeneinstellungen jederzeit ändern.

NIH Lecture Commercial Uses of Stem Cells

3.207 Aufrufe

Veröffentlicht am

A 1 hr lecture I gave at a Stem Cell workshop at the NIH, Bethesda MD on 08 Oct 09

Veröffentlicht in: Gesundheit & Medizin, Technologie
  • Als Erste(r) kommentieren

NIH Lecture Commercial Uses of Stem Cells

  1. 1. Commercial Applications of Stem Cells<br />NIH Workshop Lecture<br />Bethesda, Md Oct 8th, 2009<br />By: Jim Hardy <br />President & CSO HemaCell Perfusion, Inc.<br />
  2. 2. Background<br />Wittenberg University <br />University of Rochester<br />BRL/Life Technologies, Inc.<br />BP Solar<br />In Vitro Technologies<br />Gahaga & HemaCell Perfusion @ FITCI<br />
  3. 3. Stem Cell Market Projections and Time Line<br />RegMed 2.0<br />USD (millions)<br />1961: Canadians Jim Till & Ernest McCulloch prove the existence of stem cells (Nature 1963)<br />1978: Hematopoietic SC discovered in UCB<br />1981: mouse ES cells isolated<br />1988: HSC isolated from blood<br />1992: Adult neural SC discovered<br />1994: first Cancer SC discovered<br />1996: Dolly the Sheep<br />1998: first human ES line<br />from the Stem Cell Summit 2007 Fact Sheet: http://www.stemcellsummit.com/2007/stem-cell-fact-sheet.pdf<br />
  4. 4. The Gartner “Hype Cycle”<br />http://en.wikipedia.org/wiki/File:Gartner_Hype_Cycle.svg<br />
  5. 5. Commercial Applications of Stem Cells<br />
  6. 6. Picks and Shovels<br />Tissue sourcing, collection, isolation and banking<br />Cell Culture medium, Growth factors, cytokines, ECM proteins <br />The challenges of ex vivo expansion<br />QC Testing, characterization<br />Stem cells in Drug Discovery<br />
  7. 7. Tissue sourcing, collection, isolation and banking<br />
  8. 8. Tissue sourcing, collection, isolation and banking<br />Video About Organ & Tissue collection<br />
  9. 9. Tissue sourcing, collection, isolation and banking<br />Accredited Tissue Banks<br />Whole Organs-Transplant grade<br /> Surgical resection<br /> Birthing centers, mid-wives<br />Live donor, bone-marrow, blood collection<br />
  10. 10. Tissue sourcing, collection, isolation and banking<br />
  11. 11. Tissue sourcing, collection, isolation and banking<br />
  12. 12. Tissue sourcing, collection, isolation and banking<br /><ul><li> Density Gradient centrifugation
  13. 13. Immuno magnetic separation
  14. 14. Flow cytometry</li></li></ul><li>Tissue sourcing, collection, isolation and banking<br />Immuno magnetic separation<br />http://www.miltenyibiotec.com/Stemcell/NN_736_MACS_Cell_Separation_the_principle_1.aspx#1<br />
  15. 15. Tissue sourcing, collection, isolation and banking<br />Cell Sorting by Flow cytometry<br />
  16. 16. Tissue sourcing, collection, isolation and banking<br />Vita34, Leipzig DE http://www.vita34.de/vita/en/laboratory.php?navanchor=2110006<br />
  17. 17. Cell Culture medium, Growth factors, cytokines, ECM proteins<br />26.2 mM Na Bicarbonate<br />21 mM HEPES<br />2.2 mM Fructose<br />2 mg/mL BSA<br />10.7 g/mL L-Alanine (free base)<br />18.0 g/mL L-Asparagine –H2O<br />16.0 g/mL L-Aspartic Acid<br />17.6 g/mL L-Glutamic Acid<br />9.0 g/mLGlycine<br />13.8 g/mL L-Proline<br />12.6 g/mL L-Serine<br />135 fM Insulin<br /> 2.4 M hydrocortisone<br />10 % (v/v) serum<br />Antibiotic Mix: <br />2.04 % (v/v) Pen-Strep<br />0.05 mg/mL Gentamicin<br />0.05 mg/mL Amikacin<br />0.20 % (v/v) Fungizone<br />
  18. 18. Cell Culture medium, Growth factors, cytokines, ECM proteins <br />
  19. 19. The challenges of ex vivo expansion<br />
  20. 20. The challenges of ex vivo expansion<br />
  21. 21. The challenges of ex vivo expansion<br />Hollow Fiber Bioreactors: Fiber Cell Systems<br />
  22. 22. QC Testing & characterization (……briefly)<br /><ul><li> Microscopy
  23. 23. Flow cytometry
  24. 24. Differentiation and function
  25. 25. Proteomics
  26. 26. MicroArrays</li></ul>FORM-FIT-FUNCTION: Manufactured Parts<br />
  27. 27. Stem cells in Drug Discovery<br />As a replacement for Primary Cells<br />Skin: Wound healing & absorption models<br />Bone, cartilage<br />Hepatocytes<br />Renal cells<br />Circulatory<br />Cardiomyocytes<br />Neurons<br />Pulmonary cells<br />In vitro models for metabolic homeostasis & Organogenesis<br />Demonstrate a “stimulation” of injury & repair mechanisms<br />Inhibition of necrosis/apoptosis<br />Tissue specific developmental pathways<br />Cancer Stem Cells<br />
  28. 28. Alzheimer&apos;s Disease and neurodegeneration:<br />The modular systems biology approach to investigate the control of apoptosis in Alzheimer&apos;s disease neurodegeneration, BMC Neurosci. 2006; 7(Suppl 1): S2. <br />
  29. 29. Some of the Players<br />
  30. 30. If there is time<br />Another video<br />http://biobusiness.tv/videos/201<br />
  31. 31. Conclusions<br />A business can be built around manufacturing almost any of the tools for Stem Cell research which precedes clinical testing.<br />Stem Cell research holds the promise of a new era in medicine, a Gold Rush of sorts.<br />Before any EUREKA moment, researchers are going to need picks and shovels to find the Gold.<br /> In other words, before the FDA approves the use of manipulated cells for therapeutic purposes, investigators will need to completely understand the systems they’re working with .<br />

×